BRIEF-Actuate Therapeutics Announces Plans To Expand Clinical Pipeline, Advancing Elraglusib Tablet Into A Phase 1/2 Clinical Program In Refractory Cancers
Reuters
Jan 21
BRIEF-Actuate Therapeutics Announces Plans To Expand Clinical Pipeline, Advancing Elraglusib Tablet Into A Phase 1/2 Clinical Program In Refractory Cancers
ACTUATE THERAPEUTICS ANNOUNCES PLANS TO EXPAND CLINICAL PIPELINE, ADVANCING ELRAGLUSIB TABLET INTO A PHASE 1/2 CLINICAL PROGRAM IN REFRACTORY CANCERS
ACTUATE THERAPEUTICS INC: INITIATION OF PHASE 1 PORTION OF TRIAL PLANNED IN 2H 2026
Source text: ID:nGNXbYcDk0
Further company coverage: ACTU.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.